文献速递痛风与晶体性关节病

孤立性、代谢性与高血压性痛风:基于94759例患者的人群聚类分析

Isolated, metabolic and hypertensive gout: a population-based cluster analysis of 94 759 patients.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

总体管理欠佳,仅12%患者达到持续SU控制;代谢性痛风ULT处方率更高,但孤立性痛风依从性和SU控制更好。

要点

  • 痛风可分为孤立性、代谢性和高血压性三种临床表型,可能反映不同高尿酸血症病因。
  • 仅12%患者达到持续SU控制,所有组管理均不理想。
  • 代谢性痛风ULT处方率更高,但孤立性痛风依从性和SU控制更优。

核心结论

  • 痛风表现为三种明确区分的临床表型,分别可能反映孤立性/遗传性、胰岛素抵抗介导或肾血管性高尿酸血症病因。
  • 识别高危代谢和高血压聚类强调需要基于合并症的管理和量身定制的治疗策略。

主要发现

  • 聚类1(37.0%)为较年轻患者(平均年龄54岁),合并症较少,SU控制最佳。
  • 聚类2(22.8%)为老年患者(平均年龄74岁),2型糖尿病患病率100%,肥胖51.3%,心血管负担最重。
  • 聚类3(40.2%)为老年患者,有高血压和血脂异常但无糖尿病。
  • 总体仅12%患者达到持续SU控制(SU<6 mg/dl且占随访时间≥80%)。
  • 聚类2的ULT处方率更高,但聚类1依从性和SU控制更好。

关键数值与推荐

  • 持续SU控制定义为SU<6 mg/dl且占随访时间≥80%。
  • ULT依从性采用药物持有率(Medication Possession Ratio)评估。

临床怎么用

  • 临床应识别痛风的代谢性和高血压性表型,针对合并症进行管理并制定个体化治疗策略。
  • 需关注所有痛风患者的SU控制达标情况,尤其应提高持续SU控制率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: People with gout exhibit significant clinical heterogeneity due to diverse comorbidity profiles. This study aimed to identify distinct clinical phenotypes using cluster analysis and to evaluate differences in management, specifically urate-lowering therapy (ULT) patterns and sustained serum urate (SU) control. METHODS: A population-based retrospective cohort study was conducted using the SIDIAP database (Catalonia, Spain), including 94 759 patients with incident gout (2012-23). A K-prototypes algorithm identified clusters based on demographics and major comorbidities. Outcomes included sustained SU control (defined as SU <6 mg/dl for ≥80% of the follow-up time) and ULT adherence (Medication Possession Ratio). RESULTS: Three distinct clusters were identified. Cluster 1 (37.0%) was comprised of younger patients (mean age 54) with fewer comorbidities and the highest SU control. Cluster 2 (22.8%) included older patients (mean age 74) characterized by 100% type 2 diabetes prevalence, high obesity (51.3%), and the greatest cardiovascular burden. Cluster 3 (40.2%) featured older patients with hypertension and dyslipidaemia but no diabetes. Overall, management was suboptimal in all groups; only 12% of patients achieved sustained SU control. While Cluster 2 had higher ULT prescription rates, Cluster 1 showed better adherence and SU control. CONCLUSION: Gout manifests in three clearly differentiated clinical phenotypes, each potentially reflecting a distinct predominant aetiology of hyperuricaemia (isolated/genetic, insulin-resistance-mediated, or renal-vascular). The identification of these high-risk metabolic and hypertensive clusters underscores the need for comorbidity-driven management and tailored therapeutic strategies.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Pou MA, Martinez-Laguna D, Reyes C, et al. Isolated, metabolic and hypertensive gout: a population-based cluster analysis of 94 759 patients. Rheumatology (Oxford). 2026. PMID: 42587427. doi:10.1093/rheumatology/keag415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。